BackVallon Pharmaceuticals Overview

Vallon Pharmaceuticals Current Assets

Track Vallon Pharmaceuticals's current assets ($3.9M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$3.93M
11.25% YoYΔ $-498000.00 vs prior year quarter

Peer average

Loading

Vallon Pharmaceuticals Current Assets History

Loading

Vallon Pharmaceuticals vs. peers: Current Assets Comparison

Loading

Vallon Pharmaceuticals Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Vallon Pharmaceuticals (VLON) FAQ

Vallon Pharmaceuticals's current assets stands at $3.9M as of March 2025. That compares with $4.4M in the prior-year period — down 11.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Vallon Pharmaceuticals reported $3.9M in current assets versus $4.4M a year earlier — a 11.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $4.4M in the prior-year period — down 11.2% year over year. Sustained growth in current assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Vallon Pharmaceuticals's current assets evolved across reporting periods, while the comparison chart places VLON next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current assets is commonly used to spot outliers. Vallon Pharmaceuticals's reading of $3.9M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.